Generic Cyklokapron

Introduction

Cyklokapron is a prescription medication used in the United Kingdom to reduce excessive bleeding. The active ingredient is tranexamic acid, an antifibrinolytic agent that helps stabilise clots. Though it is listed under the broader category of Women’s Health because of its prominent role in treating heavy menstrual bleeding, the drug is also licensed for other haemostatic indications such as trauma‑related haemorrhage, dental surgery, and hereditary haemorrhagic telangiectasia. Its utility stems from a well‑documented ability to limit blood loss without directly affecting platelet function or the coagulation cascade.

What is Cyklokapron?

Cyklokapron is a branded formulation containing the synthetic amino acid derivative tranexamic acid. The medication is produced by several generic manufacturers worldwide; the specific UK‑market label is often supplied by licensed distributors rather than a single global company. Tranexamic acid is also marketed under other well‑known brand names—including Lysteda, Exacyl and Cyc‑Tranexamic —which improves its visibility in pharmacy searches.

Cyklokapron is the generic version of these brand‑name products, containing the same active compound tranexamic acid in identical strength. Our online pharmacy provides this generic alternative as a cost‑effective treatment option for patients who need reliable haemostatic control.

How Cyklokapron Works

Tranexamic acid is an antifibrinolytic that blocks the binding of lysine to plasminogen. By competitively inhibiting this interaction, the drug prevents the conversion of plasminogen to plasmin, the enzyme responsible for degrading fibrin clots. The result is a prolonged lifespan of formed clots at sites of vascular injury, thereby reducing the amount of blood that escapes through the damaged vessels.

The pharmacodynamic effect appears within 30 minutes after oral ingestion and peaks at approximately 2–3 hours. The drug’s plasma half‑life is about 2 hours in healthy adults, and it is primarily eliminated unchanged by the kidneys. Because tranexamic acid does not promote clot formation, it carries a lower theoretical risk of inducing thrombosis compared with agents that directly activate the coagulation cascade.

Conditions Treated with Cyklokapron

• Heavy Menstrual Bleeding (HMB): Recognised by NICE as a first‑line oral therapy for women whose menstrual loss exceeds 80 mL per cycle or who experience anaemia secondary to HMB.
• Trauma‑Related Bleeding: Used intravenously in the emergency setting to control haemorrhage after major injury, orthopaedic surgery, or haemorrhagic shock when rapid haemostatic support is required.
• Dental and Maxillofacial Surgery: Administered peri‑operatively to patients with congenital or acquired bleeding disorders to minimise intra‑operative blood loss.
• Hereditary Haemorrhagic Telangiectasia (HHT): Reduces epistaxis frequency and severity in individuals with this rare vascular condition.
• Other Surgical Settings: Employed off‑label in orthopaedic, cardiac, and urological procedures where excessive bleeding is anticipated.

In the United Kingdom, an estimated 1.5 million women seek treatment for HMB each year, making transexamic acid one of the most prescribed agents for menstrual disorders. Its use in trauma and surgical contexts is endorsed by national guidelines from the NHS and the British Society for Haematology.

Who is Cyklokapron For?

• Women with Heavy Menstrual Bleeding: Particularly those who have not responded adequately to hormonal therapies or who prefer a non‑hormonal option.
• Patients Undergoing Elective Surgery: Individuals on anticoagulants or with known bleeding diatheses who require additional haemostatic protection.
• Trauma Victims: Adults with acute blood loss where rapid intravenous administration is feasible.
• People with HHT: Patients experiencing frequent nosebleeds or gastrointestinal bleeding related to vascular malformations.

Cyklokapron should be avoided in patients with active intravascular clotting (e.g., deep‑vein thrombosis, pulmonary embolism) or in those with severe renal impairment (creatinine clearance < 30 mL/min) because the drug’s renal excretion may lead to accumulation and heightened thrombotic risk.

Risks, Side Effects, and Interactions

Common

• Nausea or vomiting
• Diarrhoea or abdominal discomfort
• Headache
• Dizziness (particularly after rapid intravenous infusion)

These events occur in more than 1 % of treated individuals and are typically mild, resolving without medical intervention.

Rare

• Visual disturbances (e.g., blurred vision)
• Skin rash or pruritus
• Elevated liver enzymes (transient)

Reported in less than .1 % of patients, these reactions generally do not require cessation of therapy unless they progress.

Serious

• Thromboembolic events: Deep‑vein thrombosis, pulmonary embolism, or arterial clot formation, especially in patients with pre‑existing risk factors.
• Severe hypersensitivity reactions: Anaphylaxis, angioedema, or urticaria necessitating immediate medical care.
• Renal dysfunction: Acute kidney injury has been observed in high‑dose intravenous regimens, particularly when combined with nephrotoxic drugs.

Any sign of chest pain, shortness of breath, or sudden swelling of limbs should prompt urgent evaluation.

Clinically Relevant Drug–Drug Interactions

• Oral contraceptives and hormonal replacement therapy: May increase the risk of thrombosis when combined with tranexamic acid; clinicians often assess individual clotting risk before co‑prescribing.
• Anticoagulants (warfarin, direct oral anticoagulants): Tranexamic acid may reduce the efficacy of these agents, requiring dose adjustments or close monitoring of coagulation parameters.
• Antiplatelet agents (aspirin, clopidogrel): Concurrent use can blunt the intended antifibrinolytic effect, although no major safety concern is noted.
• Renally excreted drugs (e.g., aminoglycosides, NSAIDs): Simultaneous high‑dose tranexamic acid may potentiate nephrotoxicity; dosage reduction or enhanced monitoring is advised.

Patients should disclose all current medications to the prescribing clinician to avoid unintended interactions.

Practical Use: Dosing, Missed Dose, Overdose

• Heavy Menstrual Bleeding (oral): 1 g (100 mg) taken three times daily for the first five days of menstruation. Some clinicians prescribe a lower 500 mg dose twice daily, especially in older patients.
• Trauma or Surgical Bleeding (intravenous): Initial loading dose of 10–15 mg/kg over 10 minutes, followed by a continuous infusion of 1 mg/kg/h for up to 8 hours, depending on the clinical scenario.
• Dental Surgery (oral): 1 g taken one hour before the procedure, with a second 1 g dose taken 6–8 hours post‑procedure if needed.

Missed dose: If a dose is forgotten, take it as soon as remembered provided at least 4 hours have not passed since the scheduled time. Skip the missed dose if the next dose is imminent; do not double‑dose.

Overdose: Symptoms may include nausea, vomiting, visual disturbances, and potential seizures. Management is supportive—maintain airway, provide intravenous fluids, and monitor renal function. Activated charcoal may be considered if ingestion is recent. In severe cases, haemodialysis can remove excess tranexamic acid due to its low molecular weight and limited protein binding.

Precautions:

• Take tablets with water; avoid crushing or chewing.
• Food does not significantly affect absorption, but large meals may delay onset slightly.
• Alcohol does not interact directly, but excessive intake can increase bleeding risk from other sources.
• Patients with a history of thromboembolic disease should be evaluated by a specialist before initiation.

Buying Cyklokapron from Our Online Pharmacy

Cyklokapron can be purchased safely from our online pharmacy in the UK. We specialise in offering affordable, high‑quality generic medications sourced from fully licensed overseas suppliers that meet European Medicines Agency (EMA) standards.

• Cost‑Effective Pricing: Our wholesale‑based model brings the price close to manufacturer cost, offering a substantial saving compared with standard high‑street pharmacies.
• Verified Quality: Every batch is accompanied by a Certificate of Analysis confirming identity, purity, and potency of tranexamic acid.
• Guaranteed Delivery: Discreet packaging, tracked shipping, and delivery options ranging from 7‑day express to approximately 3 weeks regular airmail.
• Online‑Only Access: For patients who encounter supply shortages or who have limited mobility, our pharmacy broker service links directly with reputable overseas licensed pharmacies, ensuring continuity of care.
• Privacy‑Focused Service: We adhere to strict data‑protection protocols, guaranteeing that personal information remains confidential throughout the ordering process.

Our platform is designed to provide a reliable, low‑cost route for individuals who might otherwise face barriers accessing Cyklokapron through conventional NHS or private pharmacy channels.

FAQ

• Is Cyklokapron available in both brand‑name and generic forms in the UK?
  Yes. The active compound tranexamic acid is marketed under the brand name Cyklokapron as well as several generic versions. Generic formulations contain the same amount of active ingredient and are typically less expensive than the proprietary brand.

• How should Cyklokapron be stored to maintain its potency?
  Store the tablets at room temperature, between 15 °C and 30 °C, in a tightly closed container away from light, moisture, and heat sources. Do not keep the medication in the bathroom or near a kitchen sink where humidity is high.

• What does the tablet look like and are there any inactive ingredients to be aware of?
  Cyklokapron tablets are usually white, round, and film‑coated, bearing the imprint “TXA 500”. Inactive components may include lactose, microcrystalline cellulose, and magnesium stearate. Patients with lactose intolerance should verify the exact formulation with the supplier.

• Can I travel internationally with Cyklokapron in my carry‑on luggage?
  Yes, provided you keep the medication in its original packaging with the label showing the generic name and dosage. It is advisable to carry a copy of the prescription or a doctor’s note, especially when entering countries with strict medication import regulations.

• Does Cyklokapron affect results of routine drug tests?
  Tranexamic acid is not a controlled substance and does not appear on standard drug‑screening panels. However, laboratories might detect it in specialized assays, which is rarely required in occupational testing.

• Are there differences in formulation between European and Asian versions of tranexamic acid?
  The active ingredient is identical worldwide, but excipients can vary. Asian formulations sometimes use different film‑coating agents or sugar‑free binders, which may be relevant for patients with specific allergies.

• Is Cyklokapron safe for use during pregnancy or breastfeeding?
  Evidence from limited observational studies suggests that tranexamic acid does not cross the placenta in harmful amounts, but it is classified as a Category B medication in the UK. It should only be used during pregnancy if the potential benefit outweighs the theoretical risk and under specialist guidance. It is excreted in breast milk in small quantities; breastfeeding mothers should discuss continuation with their clinician.

• Can Cyklokapron be combined with hormonal contraceptives without increasing clot risk?
  Co‑administration may marginally raise the risk of venous thromboembolism, especially in women who have other risk factors such as smoking or a personal history of clotting. A clinician should evaluate individual risk before prescribing both agents together.

• What is the typical shelf‑life of Cyklokapron once the bottle is opened?
  The medication remains stable for up to two years from the date of manufacture when stored correctly. Once the bottle is opened, the expiry date printed on the label still applies, but avoid prolonged exposure to moisture or extreme temperatures.

• Does the drug have any known resistance or reduced efficacy in certain patient groups?
  In rare cases, patients with severe hyperfibrinolysis may experience diminished response, necessitating higher or intravenous dosing. Additionally, individuals with markedly reduced renal clearance may accumulate the drug, prompting dose modification rather than resistance per se.

• Are there any special considerations for elderly patients taking Cyklokapron?
  Older adults often have reduced renal function, so dosage may need adjustment based on creatinine clearance. They are also more prone to thrombotic complications; careful risk assessment and monitoring are essential.

Glossary

Antifibrinolytic

A class of drugs that inhibit the breakdown of fibrin clots, thereby reducing bleeding. Tranexamic acid is a prototypical antifibrinolytic.

Tranexamic Acid

A synthetic derivative of the amino acid lysine that blocks plasminogen activation, stabilising formed clots and limiting blood loss.

Hemostasis

The physiological process that stops bleeding, involving vasoconstriction, platelet plug formation, and coagulation cascade activation.

Renal Clearance

The volume of plasma cleared of a substance by the kidneys per unit time, expressed in mL/min. Tranexamic acid is primarily eliminated unchanged through renal clearance.

⚠️ Disclaimer

The information provided about Cyklokapron is for general knowledge only. It does not replace professional medical consultation. All treatment decisions should be made under the supervision of a qualified healthcare provider. We assume all readers are responsible adults capable of making informed decisions about their health. Our online pharmacy offers access to Cyklokapron for individuals who may have limited availability through traditional pharmacies, prescription‑based insurance schemes, or who are seeking affordable generic alternatives. Always consult your doctor before starting, changing, or discontinuing any medication.